IMAC Holdings, Inc. Announces Initiation of Second Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's DiseaseĀ 

Stock Information for Issuer Direct Corporation

Loading

Please wait while we load your information from QuoteMedia.